#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anti-myelin-associated glycoprotein antibodies positive Nephropathy Insulinoma Squamous cell carcinoma of the hypopharynx Anti-myelin-associated glycoprotein associated polyneuropathy Small cell lung cancer extensive stage Pulmonary hypertension Nephrotic syndrome Necrotising myositis Epilepsy with myoclonic-atonic seizures Metastatic malignant melanoma Acute lymphocytic leukaemia Macular telangiectasia B-cell lymphoma recurrent Postprandial hypoglycaemia More trials…

    Learn about Rare Diseases

    Isodicentric chromosome 15 syndrome – Diagnostics Congenital generalised lipodystrophy Adrenogenital syndrome – Life with Disease Synovial sarcoma metastatic – Trials in Disease Myelodysplastic syndrome – Trials in Disease Chordoma – Trials in Disease Glomerulonephritis membranoproliferative – Trials in Disease Glomerulonephritis membranoproliferative – Treatment Chondrosarcoma – Life with Disease Testicular leiomyosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    S-241656 Doxycycline Hyclate SEVABERTINIB Omp11 Ecoo2 68Ganota-Anti-Her2 Vhh1 Lixisenatide Cd19-Car_Lenti_Allo Gad20-209-Fsp-A2 Urea F1245/05 ANHYDROUS CALCIUM FOLINATE Ferric Derisomaltose Levothyroxine D-Biotin LYSERGIDE Trospium Chloride Calcium Chloride Afamelanotide Dried Ferrous Sulfate More therapies…

    Learn about Your Condition

    Arteriospasm coronary Alveolar proteinosis Pleomorphic liposarcoma Gastrooesophageal cancer Malignant mast cell neoplasm Procedural headache SAPHO syndrome Anal squamous cell carcinoma Skin angiosarcoma Polycystic liver disease Perineal injury Intracranial calcification Leukaemia Pulmonary sarcoidosis Intestinal ischaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Sud Francilien

Centre Hospitalier Sud Francilien

40 Avenue Serge Dassault, Corbeil Essonnes, 91106, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Tranexamic Acid and Sodium Chloride for Patients with Stroke-Related Brain Bleeding

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cerebrovascular accident
    Investigated Drugs:
    • Tranexamic Acid
    • Sodium Chloride
    Denmark Finland France Ireland Italy Norway +2

  • Study on FOLFOX Chemotherapy for Treating Advanced Colon Cancer in Patients Aged 70 and Older

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Adenocarcinoma of colon
    Investigated Drugs:
    • Fluorouracil
    • Folinic Acid
    • Oxaliplatin
    France

  • Study on Amiodarone for Critically Ill Patients After Out-of-Hospital Cardiac Arrest with Shockable Rhythm

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Amiodarone Hydrochloride
    France

  • Study Comparing FOLFIRINOX and Cisplatin-Etoposide for Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Cisplatin
    • Etoposide
    • Fluorouracil
    France

  • Study on Avoiding Anticoagulation with Apixaban for Patients with Intracerebral Hemorrhage

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Cerebral haemorrhage
    Investigated Drugs:
    • Apixaban
    France

  • Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Blinatumomab
    • Isatuximab
    • Ponatinib
    Belgium France

  • Effect of elecoglipron plus dapagliflozin on cardiovascular outcomes in adults with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Heart failure with preserved ejection fraction
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Austria Bulgaria Czechia France Germany Greece +8

  • Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Chronic kidney disease
    Investigated Drugs:
    • Azd5004
    • Dapagliflozin
    Bulgaria Czechia Denmark Finland France Germany +8

  • Study of nemtabrutinib combined with venetoclax and obinutuzumab in untreated CLL/SLL patients with TP53 alterations

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    • Nemtabrutinib
    • Obinutuzumab
    • Venetoclax
    France

  • Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Ischaemic stroke
    Investigated Drugs:
    • Tenecteplase
    France
Previous Page
1 2 3 4 5 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!